Drug
Abrocitinib clinical trials
Also written PF-04965842 and CIBINQO.
- studies test it
- 42
- open now
- 7
- in phase 3
- 11
- first study started
- 2013
Keep track of what changes. Save the abrocitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
41 studies that test it; most in 2018 (12); 1 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 12 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 17
- Phase 2
- 10
- Phase 3
- 11
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 30 · Other 12
Pfizer (30) · Innovaderm Research Inc. (2) · Icahn School of Medicine at Mount Sinai (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Beth Israel Deaconess Medical Center (1) · William Damsky (1) · Yale University (1) · Johns Hopkins University (1)
Often tested with
Tested in the same studies.
Tofacitinib (2) · PF-06651600 (1) · Ethinyl Estradiol (1) · Levonorgestrel (1) · Midazolam (1) · Dabigatran (1) · Metformin (1) · Moxifloxacin (1)
Studies
Open first, then newest update. How each study uses abrocitinib is read from its arms, and is right about nine times in ten.
Testing it · 42
- Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down SyndromeRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT07242638Written as Abrocitinib
- A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe EczemaRecruitingPhase 3PfizerNCT06807281Written as Abrocitinib
- Abrocitinib Dose Tapering in Patients With Atopic DermatitisNot yet recruitingPhase 4Fondazione Policlinico Universitario Agostino Gemelli IRCCSNCT07848074Written as Abrocitinib
- A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe EczemaRecruitingPhase 3PfizerNCT06807268Written as Abrocitinib
- Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of AgeNot yet recruitingPhase 3PfizerNCT07823595Written as Abrocitinib
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Abrocitinib
- Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal NecrolysisRecruitingEarly Phase 1Peng ZhangNCT06119490Written as Abrocitinib
- Janus Kinase Inhibition in Granuloma AnnulareCompletedPhase 2William DamskyNCT05650736Written as Abrocitinib 200 mg
- Janus Kinase Inhibition in SarcoidosisCompletedPhase 2Yale UniversityNCT05696795Written as Abrocitinib 200 mg
- Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)Active, not recruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT05743244Written as Abrocitinib 200 MG Oral Tablet
- Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVIDActive, not recruitingPhase 2Beth Israel Deaconess Medical CenterNCT06597396Written as Abrocitinib
- Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid TherapyCompletedPhase 2Innovaderm Research Inc.NCT06283550Written as Abrocitinib 200 mg
- Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic DermatitisCompletedPhase 3PfizerNCT03422822Written as Abrocitinib 100 mg
- JAK Inhibition in Food AllergyCompletedPhase 1Icahn School of Medicine at Mount SinaiNCT05069831Written as Abrocitinib
- Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With DupilumabCompletedPhase 4Innovaderm Research Inc.NCT05602207Written as Abrocitinib
- A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.CompletedPhase 1PfizerNCT04903093Written as Abrocitinib tablet
- A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in IndiaCompletedPhase 3PfizerNCT05375929Written as Abrocitinib 100 mg
- A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy ParticipantsCompletedPhase 1PfizerNCT05067439Written as Abrocitinib
- Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown OriginCompletedPhase 2Johns Hopkins UniversityNCT05038982Written as Abrocitinib
- Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic DermatitisCompletedPhase 2PfizerNCT03915496Written as PF-04965842 200 mg
See all 42 studies that test abrocitinib →
Given in every arm · 1 — abrocitinib is usual care beside what is tested
Codes
What other systems call abrocitinib · ClinicalTrials.gg INT001172
- MeSH (NLM) C000634427abrocitinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 73SM5SF3ORABROCITINIBConfirmed FDA, NLM
- RxNorm 2591476One source FDA
- NCI Thesaurus C166985AbrocitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000634427 | abrocitinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 73SM5SF3OR | ABROCITINIB | Confirmed FDA, NLM |
| RxNorm | 2591476 | — | One source FDA |
| NCI Thesaurus | C166985 | Abrocitinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.